Literature DB >> 16364583

MR-guided intervention in women with a family history of breast cancer.

P Viehweg1, T Bernerth, M Kiechle, J Buchmann, A Heinig, H Koelbl, M Laniado, S H Heywang-Köbrunner.   

Abstract

OBJECTIVE: A study was undertaken to assess the clinical value of magnetic resonance (MR) imaging-guided interventions in women with a family history, but no personal history of breast cancer. METHODS AND PATIENTS: Retrospective review was performed on 63 consecutive women who had a family history, but no personal history of breast cancer. A total of 97 lesions were referred for an MR-guided intervention. Standardized MR examinations (1.0 T, T1-weighted 3D FLASH, 0.15 mmolGd-DTPA/kg body weight, prone position) were performed using a dedicated system which allows vacuum assisted breast biopsy or wire localization.
RESULTS: Histologic findings in 87 procedures revealed 9 (10%) invasive carcinomas, 12 (14%) ductal carcinomas in situ, 2 atypical ductal hyperplasias (2.5%) and 2 atypical lobular hyperplasias (2.5%). Sixty-two (71%) benign histologic results are verified by an MR-guided intervention, retrospective correlation of imaging and histology and by subsequent follow-up. In ten lesions the indication dropped since the enhancing lesion was no longer visible. Absent enhancement was confirmed by short-term re-imaging of the noncompressed breast and by follow-up.
CONCLUSION: Malignancy was found in 24%, high-risk lesions in 5% of successfully performed MR-guided biopsy procedures. A 57% of MR-detected malignancies were ductal carcinoma in situ. In 10% of the lesions the intervention was not performed, since no enhancing lesion could be reproduced at the date of anticipated intervention. Such problems may be avoided if the initial MRI is performed in the appropriate phase of the menstrual cycle and without hormonal replacement therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16364583     DOI: 10.1016/j.ejrad.2005.09.004

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  7 in total

1.  Radio-guided occult lesion localisation for breast lesions under computer-aided MRI guidance: the first experience and initial results.

Authors:  M H Yilmaz; F Kilic; G E Icten; F Aydogan; V Ozben; M Halac; D C Olgun; E Gazioglu; V Celik; C Uras; Z A Altug
Journal:  Br J Radiol       Date:  2011-10-18       Impact factor: 3.039

2.  MR-guided stereotactic breast biopsy using a mixed ferromagnetic-nonmagnetic coaxial system with 12- to 18-gauge needles: clinical experience and long-term outcome.

Authors:  Elena Belloni; Pietro Panizza; Silvia Ravelli; Francesco De Cobelli; Simone Gusmini; Claudio Losio; Isabella Sassi; Gianluca Perseghin; Alessandro Del Maschio
Journal:  Radiol Med       Date:  2013-06-25       Impact factor: 3.469

3.  Magnetic Resonance Imaging Guided Vacuum Assisted and Core Needle Biopsies.

Authors:  Fahrettin Kılıç; Abdulkadir Eren; Necmettin Tunç; Mehmet Velidedeoğlu; Selim Bakan; Fatih Aydoğan; Varol Çelik; Ertuğrul Gazioğlu; Mehmet Halit Yılmaz
Journal:  J Breast Health       Date:  2016-01-01

4.  Auditing a breast MRI practice: performance measures for screening and diagnostic breast MRI.

Authors:  Bethany L Niell; Sara C Gavenonis; Tina Motazedi; Jessica Cott Chubiz; Elkan P Halpern; Elizabeth A Rafferty; Janie M Lee
Journal:  J Am Coll Radiol       Date:  2014-04-29       Impact factor: 5.532

Review 5.  [Value of breast MRI as supplement to mammography and sonography for high risk breast cancer patients].

Authors:  T Schlossbauer; K Hellerhoff; M Reiser
Journal:  Radiologe       Date:  2008-04       Impact factor: 0.635

6.  Patient outcomes in canceled MRI-guided breast biopsies.

Authors:  Bethany L Niell; Janie M Lee; Christopher Johansen; Elkan F Halpern; Elizabeth A Rafferty
Journal:  AJR Am J Roentgenol       Date:  2014-01       Impact factor: 3.959

Review 7.  Overdiagnosis and overtreatment of breast cancer: is overdiagnosis an issue for radiologists?

Authors:  Ruth Warren; Asha Eleti
Journal:  Breast Cancer Res       Date:  2006-04-21       Impact factor: 6.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.